<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="228358">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00108589</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-014-03S</org_study_id>
    <nct_id>NCT00108589</nct_id>
  </id_info>
  <brief_title>S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis</brief_title>
  <official_title>S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of S-adenosylmethionine therapy in those
      patients with non-alcoholic liver disease in the form of steatohepatitis (NASH). This will
      be accomplished by development of a database of these patients, all of whom will have biopsy
      documented NASH. A placebo controlled trial will then examine the effect of
      S-adenosylmethionine over time on clinical outcome in these patients. It is expected that
      this agent will slow or halt the progression of this disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <condition>Hepatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-adenosylmethionine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men with biopsy proven non-alcoholic steatohepatitis from the liver disease clinic or
             referred from other physicians from the VAMC-Louisville.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <lastchanged_date>January 20, 2009</lastchanged_date>
  <firstreceived_date>April 15, 2005</firstreceived_date>
  <keyword>s-adenosylmethionine</keyword>
  <keyword>fatty liver</keyword>
  <keyword>obesity</keyword>
  <keyword>Non-alcoholic steatohepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
